VNRX: Reports 3Q 2024 results. Over 110
Volition's Nu.Q Vet Canine Cancer Screening Test now available in 17 countries, particularly by Antech on its Element I+ diagnostic...
174 Views
VNRX: Cost cutting being implemented in a plan to be cash flow neutral in 2025. Revenues from Nu.Q Vet Test Expected to Accelerate During 2H 2024
Volition's Nu.Q Vet Canine Cancer Screening Test are being launched in the U.S. and Europe by Antech on its Element I+ diagnostic point-of-sale...
143 Views
VolitionRx - Snaring sepsis, with early NETs detection
VolitionRx continues to make headway in growing a body of clinical evidence to build Nu.Q® NETs as a potential breakthrough tool in sepsis. These...
207 Views
VolitionRx - Vetting the pet health opportunity
While pets are increasingly being ‘humanized’, their healthcare has lagged advancements seen on the human side. With the COVID-19 pandemic...
107 Views
VolitionRx - Unravelling the web of NETs in sepsis
VolitionRx is a clinical diagnostics company with a different perspective on immunoassay technology for the detection and monitoring of severe...
670 Views